Rich-Henry represents life science and biotech companies in all areas of patent counseling, including life cycle management, patent portfolio development and restructuring, post-issuance proceedings, investment and transactional intellectual property due diligence, and offensive and defensive patent strategy for startups, established companies, and VC firms. A patent attorney registered before the U.S. Patent & Trademark Office, he has a strong background in biomedical science and biotechnology, including a Ph.D. in Microbiology and Immunology, which enables him to bring a meticulous, detail-oriented approach to protecting client’s intellectual property and ensuring such strategies align with their business objectives.
He handles all aspects of patent prosecution and counseling on behalf of clients and has extensive experience in patent preparation and prosecution, post-grant proceedings, the development/management of patent portfolios in the U.S. and abroad, and due diligence.
Rich-Henry has extensive experience with investor-side and company-side patent due diligence and has led or participated in patent due diligence reviews ranging in size from small seed investments to large acquisitions in the biotechnology, medical device, drug delivery, and pharmaceutical fields. He is experienced in opinion work, including freedom to operate, validity, infringement, patent landscape, and patentability opinions.
Technical areas of his patent portfolio development and management, opinion and due diligence work include all areas of biotechnology (including immunology, cell and molecular biology, virology, bacteriology, genetics, and biochemistry), medical devices, the chemical arts, and pharmaceuticals. Specific examples include human and veterinary vaccines, including polypeptide/peptide design for shared and personalized cancer vaccines, antibodies and antibody engineering, recombinant nucleic acids and proteins, methods of treating human and animal diseases, gene therapies, screening and diagnostic assays, biomarkers, diagnostic agents, animals and cell lines, pharmaceuticals, isothermal nucleic acid amplification, stents and balloon angioplasty devices, and implantable devices.
In his post-issuance practice, whether in post-grant review proceedings or in patent litigation, Rich-Henry works synergistically with litigation counsel, conducting analysis, developing strategy and validity positions, and working directly with experts to find efficient, business-oriented solutions. He served as counsel on a team successfully defending a series of biotechnology patents of a Fortune 100 company in Inter Partes Review proceedings before the U.S. Patent & Trademark Office. Further, he has acted as a technical liaison between trial counsel and expert witnesses during a multimillion-dollar medical device litigation and has served to manage foreign counsel in various European oppositions and appeals.
Prior to practicing law, Rich-Henry worked on the development of novel vaccine adjuvant systems at the Institute of Cellular Therapeutics at the University of Louisville School of Medicine. He previously served as an AmeriCorps team leader, where he further developed his leadership and management abilities.
- Brandeis School of Law at the University of Louisville (J.D., cum laude)
- Brandeis Scholar, 2013
- University of Louisville School of Medicine (Ph.D., 2010)
- Microbiology and Immunology
- University of Louisville School of Medicine (M.S., 2006)
- University of Virginia (B.A., 2005)
- U.S. Patent & Trademark Office
- Not licensed in Connecticut